Almost two years have passed since the outbreak of the pandemic, during which hundreds of thousands of scientific publications related to COVID-19 have been published. Hence, can we say that we already know everything about SARS-CoV-2? Our scientists Ahmed Abdeen Hamed and Karolina L. Tkaczuk, in their latest article, published in Pharmaceutics, pose a bold question whether the combination of FDA-approved drugs may be considered as a candidate for COVID-19 treatment and provide specific answers to it. All this with using a computational framework that can undeniably revolutionize therapy planning and implementation of innovative treatments.